Anavex Life Sciences Corp (AVXL)

[williamssc]

--Complete data ANAVEX®2-73 U.S. adult Rett syndrome (RTT) Phase 2 study
--Complete data ANAVEX®2-73 Parkinson’s disease dementia (PDD) Phase 2 study
--Top-line data Phase 1 ANAVEX®3-71 clinical trial
--Top-line data AVATAR: Potentially pivotal Phase 3 adult RTT ANAVEX®2-73 clinical trial
> Top-line data ANAVEX®2-73-AD-004: Potentially pivotal Phase 2b/3 AD clinical trial -- expected fall 2022
> Data of 48-week OLE PDD Phase 2 study – expected by end 2022
> EXCELLENCE completion: Potentially pivotal Phase 2/3 pediatric RTT clinical trial -- expected by end 2022
> Initiation of ANAVEX®2-73 imaging-focused Parkinson’s disease clinical trial – expected 2022
> Initiation of potentially pivotal ANAVEX®2-73 Phase 2/3 Fragile X clinical trial – expected 2022
> Initiation of potentially pivotal ANAVEX®2-73 Phase 2/3 clinical trial for the treatment of a new, rare disease indication – expected 2022
> Initiation of ANAVEX®3-71 Phase 2 clinical trial for FTD, schizophrenias and Alzheimer’s disease – expected 2022

The company has multiple clinical milestones Catalysts to Drive Value
Page15